Respiratory News and Research RSS Feed - Respiratory News and Research

3D respiratory tissue model shown to be effective for measuring impact of chemicals

3D respiratory tissue model shown to be effective for measuring impact of chemicals

A 3-dimensional model of human respiratory tissue has been shown to be an effective platform for measuring the impact of chemicals, like those found in cigarette smoke, or other aerosols on the lung. [More]
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Metabolic imbalance can trigger respiratory diseases in early childhood

Metabolic imbalance can trigger respiratory diseases in early childhood

An imbalance in our metabolism can trigger inflammatory processes in the body and activate the immune system. In a recent study, published in the Journal of Allergy and Clinical Immunology, UFZ researchers have been able to show that this applies even to newborns and children under one year of age, and is correlated with the development of respiratory diseases in early childhood. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
First randomized, controlled trial of pharmacotherapy in PCD patients now in place

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe. [More]
Researchers use genetic information to track the fatal spread of multidrug-resistant TB

Researchers use genetic information to track the fatal spread of multidrug-resistant TB

Scientists have for the first time used DNA sequencing to trace the fatal spread of multidrug-resistant tuberculosis between patients in the UK. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Experts call for global review of sepsis guidelines

Experts call for global review of sepsis guidelines

Experts are calling for a global review of guidelines used to diagnose sepsis, after a study found one in eight patients with infections severe enough to need admission to an Intensive Care Unit in Australia and New Zealand, did not meet current criteria. [More]
WHO calls for intensification of routine immunization services in all Ebola-affected areas

WHO calls for intensification of routine immunization services in all Ebola-affected areas

A growing risk of outbreaks of measles, pertussis, and other vaccine-preventable diseases in countries affected by Ebola must be countered by urgent scaling up of routine immunization activities, according to the World Health Organization. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Healthcare systems miss life-saving treatments learnt on battlefield

Healthcare systems miss life-saving treatments learnt on battlefield

Trauma is responsible for more global deaths annually than HIV, malaria and tuberculosis combined. Yet healthcare systems in many countries are missing out on life-saving treatments learnt on the battlefield, according to a review by King's College London and published today in the Journal of the Royal Society of Medicine. [More]
Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Cambridge scientists successfully create 'mini-lungs' to study cystic fibrosis

Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease. [More]
Survey: Number of UK adults living with cystic fibrosis expected to increase by 2025

Survey: Number of UK adults living with cystic fibrosis expected to increase by 2025

The number of people living with cystic fibrosis into adulthood in the UK is expected to increase dramatically - by as much as 80 per cent - by 2025, according to a Europe-wide survey, the UK end of which was led by Queen's University Belfast. [More]
AIR Louisville to use digital health technology to improve asthma

AIR Louisville to use digital health technology to improve asthma

Today marks the start of AIR Louisville, the first-of-its-kind data-driven collaboration among public, private and philanthropic organizations to use digital health technology to improve asthma. Kentucky has the fourth highest adult asthma prevalence in the US and Louisville consistently ranks among the top 20 "most challenging" cities to live in with asthma. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
MSU researchers discover cause of death in children who get malaria

MSU researchers discover cause of death in children who get malaria

Researchers from Michigan State University have uncovered the cause of death in children who die from cerebral malaria. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
BD announces completion of CareFusion acquisition

BD announces completion of CareFusion acquisition

Becton, Dickinson and Company today announced that it completed its acquisition of CareFusion Corporation pursuant to the terms of its previously announced Agreement and Plan of Merger, dated October 5, 2014 (the "Merger Agreement"). [More]
Researchers identify new gene variants that could contribute to sporadic motor neurone disease

Researchers identify new gene variants that could contribute to sporadic motor neurone disease

Researchers have identified a new host of gene variants that could make people vulnerable to sporadic motor neurone disease, according to a report published today in the journal, Scientific Reports. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
Advertisement
Advertisement